Thursday, 26 April 2012

Iloperidonesee


Class: Atypical Antipsychotics
VA Class: CN709
Chemical Name: 4’-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3’-methoxyacetophenone
Molecular Formula: C24H27FN2O4
CAS Number: 133454-47-4
Brands: Fanapt


  • Increased Mortality in Geriatric Patients with Dementia-related Psychosis


  • Geriatric patients with dementia-related psychosis treated with antipsychotic agents are at an increased risk of death.1 22 23




  • Analyses of 17 placebo-controlled trials in geriatric patients mainly receiving atypical antipsychotic agents revealed an approximate 1.6- to 1.7-fold increase in mortality compared with that in patients receiving placebo.1 23




  • Most fatalities appeared to result from cardiovascular-related events (e.g., heart failure, sudden death) or infections (mostly pneumonia).1 23




  • Observational studies suggest that conventional or first-generation antipsychotic agents also may increase mortality in such patients.1 22




  • Antipsychotic agents, including iloperidone, are not approved for the treatment of dementia-related psychosis.1 22 23




Introduction

Piperidinyl-benzisoxazole derivative; atypical or second-generation antipsychotic agent.1 3 4 6 7 8 9 10 11 12 13 14 15 87


Uses for Iloperidonesee


Schizophrenia


Acute treatment of schizophrenia in adults.1 2 4 5


American Psychiatric Association (APA) considers most atypical antipsychotic agents first-line drugs for the management of the acute phase of schizophrenia (including first psychotic episodes).16


Patients who do not respond to or tolerate one drug may be successfully treated with an agent from a different class or with a different adverse effect profile.16 17 18 19


When deciding among treatment alternatives, consider that iloperidone may prolong the QT interval.1 Some other drugs that prolong the QT interval cause torsades de pointes-type arrhythmia; it is not yet known whether iloperidone causes torsades de pointes or increases the rate of sudden death.1 In many cases, other drugs should be tried first.1 (See Prolongation of QT Interval under Cautions.)


Because iloperidone must be titrated to an effective dosage, symptom control may be more delayed during first 1–2 weeks of therapy compared with some other antipsychotic agents that do not require similar titration.1 (See Dosage under Dosage and Administration.) Keep this delay in mind when selecting an agent for acute treatment of schizophrenia.1


Iloperidonesee Dosage and Administration


General



  • When switching from other antipsychotic agents to iloperidone, abrupt discontinuance of previous agent may be acceptable for some patients with schizophrenia, but gradual discontinuance may be most appropriate for others.1 In all cases, minimize period of overlapping antipsychotic administration.1



Administration


Oral Administration


Administer tablets orally twice daily without regard to meals.1 However, administration with food may minimize adverse effects.8


Dosage


Must titrate slowly from a low initial dosage to avoid orthostatic hypotension;1 87 therefore, symptom control may be delayed during first 1–2 weeks of therapy.1 (See Orthostatic Hypotension and Syncope under Cautions and see Schizophrenia under Uses.)


Follow initial titration schedule if treatment has been interrupted for >3 days.1


Some of the drug’s adverse effects are dose related.1


Adults


Schizophrenia

Oral

For acute treatment, initial dosage is 1 mg twice daily.1 87 Dosage increases to reach the recommended target dosage range of 6–12 mg twice daily may be made with daily dosage adjustments to 2, 4, 6, 8, 10, and 12 mg twice daily on days 2, 3, 4, 5, 6, and 7, respectively.1 87


Optimum duration of therapy is not known, but maintenance therapy with antipsychotics is well established.1 16 In responsive patients, continue drug therapy beyond the acute response and as long as clinically necessary and tolerated; periodically reassess need for continued therapy.1 16


In patients with remitted first or multiple episodes, APA recommends either indefinite maintenance therapy or gradual discontinuance of the antipsychotic with close follow-up and a plan to reinstitute treatment upon symptom recurrence.16 Consider antipsychotic therapy discontinuance only after ≥1 year of symptom remission or optimal response while receiving the drug.16 Indefinite maintenance antipsychotic treatment is recommended if patient has experienced multiple previous psychotic episodes or 2 episodes within 5 years.16


Prescribing Limits


Adults


Schizophrenia

Oral

Maximum 12 mg twice daily.1


Special Populations


Hepatic Impairment


Use not recommended in patients with any degree of hepatic impairment.1 15 (See Special Populations under Pharmacokinetics.)


Renal Impairment


Routine dosage adjustment not required.1 (See Renal Impairment under Cautions and see Special Populations under Pharmacokinetics.)


Geriatric Patients


Routine dosage adjustment not required.1


Gender or Race


No dosage adjustment necessary based on gender or race.1


Concomitant Use with CYP2D6 and/or CYP3A4 Inhibitors


Reduce iloperidone dosage by 50% if administered concomitantly with potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) or potent CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole).1 May resume previous iloperidone dosage upon discontinuance of the potent CYP2D6 or CYP3A4 inhibitor.1


Also reduce iloperidone dosage by 50% when given in combination with both a CYP2D6 and CYP3A4 inhibitor.1 (See Interactions.)


Poor Metabolizers of CYP2D6


Reduce dosage by 50%;1 exposure to iloperidone is higher in poor metabolizers of CYP2D6 than in extensive metabolizers.1 10 Laboratory tests are available to identify poor CYP2D6 metabolizers.1 (See Special Populations and also see Elimination under Pharmacokinetics.)


Cautions for Iloperidonesee


Contraindications



  • Known hypersensitivity (e.g., pruritus, urticaria) to iloperidone or to any ingredient in the formulation.1



Warnings/Precautions


Warnings


Increased Mortality in Geriatric Patients with Dementia-related Psychosis

Increased risk of death with use of either conventional (first-generation) or atypical (second-generation) antipsychotics in geriatric patients with dementia-related psychosis.1 22 23 25


Antipsychotic agents, including iloperidone, are not approved for the treatment of dementia-related psychosis.1 22 23 (See Increased Mortality in Geriatric Patients with Dementia-related Psychosis in Boxed Warning, see Cerebrovascular Events in Geriatric Patients with Dementia-related Psychosis under Cautions, and see Dysphagia under Cautions.)


Other Warnings and Precautions


Cerebrovascular Events in Geriatric Patients with Dementia-related Psychosis

Increased incidence of adverse cerebrovascular events (cerebrovascular accidents and TIAs), including fatalities, observed in geriatric patients with dementia-related psychosis treated with certain atypical antipsychotic agents (aripiprazole, olanzapine, risperidone) in placebo-controlled studies.1 Iloperidone is not approved for the treatment of dementia-related psychosis.1 (See Increased Mortality in Geriatric Patients with Dementia-related Psychosis in Boxed Warning.)


Prolongation of QT Interval

Corrected QT (QTc) interval prolonged by 2.9, 3.9, and 9.1 msec at total daily dosages of 4–8, 10–16, and 20–24 mg, respectively.1 5 14 CYP2D6 or CYP3A4 inhibition increases this effect; under conditions of both CYP2D6 and CYP3A4 inhibition, mean QTc interval (corrected using Fridericia’s formula) was prolonged by about 19 msec at dosage of 12 mg twice daily.1 No cases of torsades de pointes or other severe cardiac arrhythmias reported during premarketing clinical trials.1


Factors that may increase the risk of torsades de pointes and/or sudden death in association with drugs that prolong the QTc interval include bradycardia, hypokalemia or hypomagnesemia, concomitant use of other drugs that prolong the QTc interval, presence of congenital prolongation of the QT interval, recent acute MI, and/or uncompensated heart failure.1


Avoid concomitant use of other drugs known to prolong the QTc interval (see Interactions).1 Also avoid use in patients with congenital QT-interval prolongation or a history of cardiac arrhythmias.1


Use with caution in patients concurrently receiving drugs that inhibit iloperidone’s metabolism and in patients with reduced CYP2D6 activity (see Special Populations under Dosage and Administration and see Interactions).1


Hypokalemia and/or hypomagnesemia may increase the risk of QT prolongation and cardiac arrhythmias.1 Manufacturer recommends baseline and periodic monitoring of serum potassium and magnesium in patients at risk for disturbances of these electrolytes.1


Avoid use of iloperidone in patients with a history of clinically important cardiovascular illness (e.g., QT-interval prolongation, recent acute MI, uncompensated heart failure, cardiac arrhythmia).1


Discontinue iloperidone therapy in patients with persistent QTc interval measurements >500 msec.1 Further evaluation, including cardiac monitoring, is recommended in patients with symptoms suggestive of cardiac arrhythmias (e.g., dizziness, palpitations, syncope).1


Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome (NMS), a potentially fatal syndrome characterized by hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability, reported with antipsychotic agents.1


Immediately discontinue therapy and initiate supportive and symptomatic therapy if NMS occurs.1 Careful monitoring recommended if therapy is reinstituted following recovery; the risk that NMS can recur must be considered.1


Tardive Dyskinesia

Tardive dyskinesia, a syndrome of potentially irreversible, involuntary, dyskinetic movements, reported with use of antipsychotic agents.1


Reserve long-term antipsychotic treatment for patients with chronic illness known to respond to antipsychotic agents, and for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate.1 In patients requiring chronic treatment, use smallest dosage and shortest duration of treatment producing a satisfactory clinical response; periodically reassess need for continued therapy.1


APA recommends assessing patients receiving atypical antipsychotic agents for abnormal involuntary movements every 12 months; for patients at increased risk for tardive dyskinesia, assess every 6 months.16 Consider discontinuance of iloperidone if signs and symptoms of tardive dyskinesia appear.1 However, some patients may require treatment despite presence of the syndrome.1


Hyperglycemia and Diabetes Mellitus

Hyperglycemia, sometimes severe and associated with ketoacidosis, hyperosmolar coma, or death, reported in patients receiving atypical antipsychotic agents, including iloperidone.1 26 27 28 29 30 31 32 33 34 35 36 39 52 53 54 58 77 Clinically important differences between iloperidone and placebo in mean change from baseline to end point in serum glucose concentrations not observed in short-term clinical trials.1


Closely monitor patients with preexisting diabetes mellitus for worsening of glucose control and perform fasting blood glucose testing at baseline and periodically in patients with risk factors for diabetes (e.g., obesity, family history of diabetes).1 26 27 28 29 30 31 32 33 34 35 36 37 If manifestations of hyperglycemia occur in any iloperidone-treated patient, perform fasting blood glucose testing.1 26 27 28 29 30 31 32 33 34 35 36 37


Some patients who developed hyperglycemia while receiving an atypical antipsychotic have required continuance of antidiabetic treatment despite discontinuance of the suspect drug; in other patients, hyperglycemia resolved with discontinuance of the antipsychotic.1 26 27 28 29 30 31 32 33 34 35 36 37 58


Weight Gain

Mean weight gain of 2 kg reported during short-term studies; weight gain was ≥7% of baseline body weight in 12 or 18% of patients receiving iloperidone 10–16 or 20–24 mg daily, respectively.1 (See Hyperglycemia and Diabetes Mellitus under Cautions.)


Seizures

Seizures occurred in 0.1% of iloperidone-treated patients compared with 0.3% of placebo recipients in short-term clinical trials.1


Use with caution in patients with a history of seizures or with conditions that may lower the seizure threshold (e.g., dementia of the Alzheimer’s type); conditions that lower the seizure threshold may be more prevalent in patients ≥65 years of age.1


Orthostatic Hypotension and Syncope

Risk of orthostatic hypotension associated with dizziness, tachycardia, and syncope, particularly when initiating or reinitiating therapy or increasing the dosage, because of iloperidone’s α1-adrenergic blocking activity.1 5


Syncope reported in 0.4% of iloperidone-treated patients when dosage was increased slowly as recommended in short-term clinical trials.1 Orthostatic hypotension reported in 3 or 5% of patients receiving iloperidone 10–16 or 20–24 mg daily, respectively.1 Increased incidence of orthostatic hypotension and syncope would be expected with more rapid dosage titration.1 14 (See Dosage under Dosage and Administration.)


Use with caution in patients with known cardiovascular disease (e.g., heart failure, history of MI, ischemic heart disease, conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (e.g., dehydration, hypovolemia, concomitant antihypertensive therapy).1 Consider monitoring orthostatic vital signs in patients who are susceptible to hypotension.1


Hematologic Effects

Leukopenia and neutropenia temporally related to antipsychotic agents.1 78 Agranulocytosis (including fatal cases) also reported with antipsychotic agents.1


Possible risk factors for leukopenia and neutropenia include preexisting low WBC count and a history of drug-induced leukopenia or neutropenia.1 78 Monitor CBC frequently during the first few months of therapy in patients with such risk factors.1 Discontinue iloperidone at the first sign of a decline in WBC count in the absence of other causative factors.1


Carefully monitor patients with clinically important neutropenia for signs and symptoms of infection (e.g., fever) and treat promptly if they occur.1 Discontinue iloperidone if severe neutropenia (ANC <1000/mm3) occurs; monitor WBC until recovery occurs.1


Hyperprolactinemia

May cause elevated serum prolactin concentrations, which may persist during chronic administration and cause clinical disturbances (e.g., galactorrhea, amenorrhea, gynecomastia, impotence).1 10 16 Chronic hyperprolactinemia associated with hypogonadism may lead to decreased bone density in both females and males.1 16


In short-term trials, iloperidone was associated with relatively modest elevations in prolactin concentrations compared with some other antipsychotic agents (e.g., first-generation antipsychotics including haloperidol, risperidone).1 10 16


If contemplating iloperidone therapy in a patient with previously detected breast cancer, consider that approximately one-third of human breast cancers are prolactin-dependent in vitro.1 16


Body Temperature Regulation

Antipsychotic agents may disrupt ability to regulate core body temperature.1


Use appropriate caution in patients subjected to conditions that may contribute to an elevation in core body temperature (e.g., strenuous exercise, extreme heat, concomitant use of agents with anticholinergic activity, dehydration).1


Dysphagia

Esophageal dysmotility and aspiration associated with the use of antipsychotic agents.1


Aspiration pneumonia is a common cause of morbidity and mortality in geriatric patients, particularly those with advanced Alzheimer’s dementia.1 Use with caution in patients at risk for aspiration pneumonia.1 Iloperidone is not approved for the treatment of patients with dementia-related psychosis.1 (See Increased Mortality in Geriatric Patients with Dementia-related Psychosis in Boxed Warning.)


Suicide

Attendant risk with psychotic illnesses; closely supervise high-risk patients.1 Prescribe in the smallest quantity consistent with good patient management to reduce the risk of overdosage.1


Priapism

Priapism reported in patients receiving drugs with α-adrenergic blocking activity, including iloperidone.1 Severe priapism may require surgical intervention.1


Cognitive and Motor Impairment

Judgment, thinking, or motor skills may be impaired.1 Somnolence (including sedation) reported in about 12% of patients receiving iloperidone dosages ≥10 mg daily.1 (See Advice to Patients.)


Specific Populations


Pregnancy

Category C.1


Risk for extrapyramidal and/or withdrawal symptoms (e.g., agitation, hypertonia, hypotonia, tardive dyskinetic-like symptoms, tremor, somnolence, respiratory distress, feeding disorder) in neonates exposed to antipsychotic agents during the third trimester; monitor neonates exhibiting such symptoms.1 88 89 90 Symptoms were self-limiting in some neonates but varied in severity; some infants required intensive support and prolonged hospitalization.1 88 89 90


Lactation

Iloperidone distributes into milk in rats; not known whether iloperidone and/or its metabolites distribute into human milk.1 Women receiving iloperidone should not breast-feed.1


Pediatric Use

Safety and efficacy not established in pediatric and adolescent patients.1


Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether they respond differently than younger adults.1


Geriatric patients with dementia-related psychosis treated with either conventional or atypical antipsychotic agents are at an increased risk of death;1 22 23 increased incidence of cerebrovascular events also observed with certain atypical antipsychotic agents.1 Iloperidone is not approved for the treatment of dementia-related psychosis.1 (See Increased Mortality in Geriatric Patients with Dementia-related Psychosis in Boxed Warning and see Cerebrovascular Events in Geriatric Patients with Dementia-related Psychosis under Cautions.)


Hepatic Impairment

Use not recommended in patients with any degree of hepatic impairment.1 15 (See Special Populations under Pharmacokinetics.)


Renal Impairment

Renal impairment is unlikely to substantially alter the pharmacokinetics of iloperidone; the drug is highly metabolized (<1% excreted unchanged).1 15 (See Special Populations under Pharmacokinetics.) Routine dosage adjustment is not necessary.1


Common Adverse Effects


Dizziness,1 2 5 somnolence or sedation,1 2 5 fatigue,1 5 dry mouth,1 2 5 nasal congestion,1 2 5 tachycardia,1 2 orthostatic hypotension,1 2 weight gain.1 2


Interactions for Iloperidonesee


Primarily metabolized by CYP2D6 and CYP3A4.1 8 9 10 Iloperidone is not a substrate for CYP isoenzymes 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, or 2E1 and does not induce isoenzymes 1A2, 2C8, 2C9, 2C19, 3A4, or 3A5 in vitro.1


Drugs Affecting Hepatic Microsomal Enzymes


CYP3A4 and CYP2D6 inhibitors: Potential pharmacokinetic interaction (inhibition of iloperidone clearance resulting in increased plasma concentrations).1 Reduce iloperidone dosage by 50% if used concomitantly with a potent inhibitor of CYP2D6 or CYP3A4; may resume previous iloperidone dosage upon discontinuance of the CYP2D6 or CYP3A4 inhibitor.1 Also reduce iloperidone dosage by 50% when given in combination with both a CYP2D6 and CYP3A4 inhibitor.1


Drug interaction studies have evaluated effects of certain potent CYP3A4 or CYP2D6 inhibitors on iloperidone pharmacokinetics (see Specific Drugs under Interactions).1 Concomitant administration with weaker CYP3A4 inhibitors not studied.1 Effects of other potent CYP2D6 inhibitors expected to be similar to those of fluoxetine or paroxetine.1


Inhibitors or inducers of CYP isoenzymes 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, or 2E1: Pharmacokinetic interactions are unlikely.1


Drugs Metabolized by Hepatic Microsomal Enzymes


Substrates of CYP isoenzymes 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, or 3A5: Pharmacokinetic interactions are unlikely.1 (See Specific Drugs under Interactions.)


Iloperidone does not substantially inhibit the metabolism of drugs metabolized by CYP isoenzymes 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, or 2E1 in vitro.1


Drugs that Prolong QT Interval


Potential additive effect on QT-interval prolongation; avoid concomitant use of other drugs known to prolong the QTc interval.1 42 81 82 83 87 (See Prolongation of QT Interval under Cautions and see Specific Drugs under Interactions.)


Specific Drugs




























































Drug



Interaction



Comments



Alcohol



Possible additive CNS effects1



Avoid concomitant use1



Antiarrhythmics, class IA and III (e.g., amiodarone, procainamide, quinidine, sotalol)



Increased risk of QT-interval prolongation1



Avoid concomitant use1



Anticholinergic agents



Possible disruption of body temperature regulation1



Use with caution1



Antipsychotic agents that prolong QT interval (e.g., asenapine, chlorpromazine, haloperidol, olanzapine, paliperidone, pimozide, quetiapine, thioridazine, ziprasidone)



Increased risk of QT-interval prolongation1 42 81



Avoid concomitant use1



Clarithromycin



Possible increase in AUCs of iloperidone and its P88 and P95 metabolites during concurrent administration1



Use with caution and reduce iloperidone dosage by about 50% during concurrent administration; resume previous iloperidone dosage upon discontinuance of clarithromycin1


Reduce iloperidone dosage by about 50% if given concurrently with both clarithromycin (a CYP3A4 inhibitor) and a CYP2D6 inhibitor1



CNS agents



Possible additive CNS effects1



Use with caution1



Dextromethorphan



17% increase in total exposure and 26% increase in peak plasma concentrations of dextromethorphan during concurrent administration1



Fluoxetine



Approximate twofold to threefold increase in AUC of iloperidone and its P88 metabolite and 50% decrease in AUC of its P95 metabolite during concurrent administration in extensive CYP2D6 metabolizers1


Single dose of iloperidone did not affect fluoxetine pharmacokinetics1



Use with caution and reduce iloperidone dosage by 50% during concurrent administration; resume previous iloperidone dosage upon discontinuance of fluoxetine1


Reduce iloperidone dosage by about 50% if given concurrently with both fluoxetine (a CYP2D6 inhibitor) and a CYP3A4 inhibitor1



Gatifloxacin



Increased risk of QT-interval prolongation1



Avoid concomitant use1



Hypotensive agents



Possible additive hypotensive effects; may result in orthostatic hypotension and syncope1



Use with caution; consider monitoring orthostatic vital signs and reducing iloperidone dosage if hypotension develops1



Itraconazole and ketoconazole



Concomitant administration of ketoconazole and iloperidone increased AUCs of iloperidone and its P88 and P95 metabolites by 57, 55, and 35%, respectively1



Use with caution and reduce iloperidone dosage by about 50% during concurrent administration; resume previous iloperidone dosage upon discontinuance of itraconazole or ketoconazole1


Reduce iloperidone dosage by about 50% if given concurrently with both a CYP2D6 inhibitor and either itraconazole or ketoconazole (CYP3A4 inhibitors)1



Levomethadyl acetate (no longer commercially available in US)



Increased risk of QT-interval prolongation1



Avoid concomitant use1



Methadone



Increased risk of QT-interval prolongation1



Avoid concomitant use1



Moxifloxacin



Increased risk of QT-interval prolongation1



Avoid concomitant use1



Paroxetine



Approximate 1.6-fold increase in mean steady-state peak plasma concentrations of iloperidone and its P88 metabolite and 50% decrease in mean steady-state peak plasma concentrations of its P95 metabolite during concurrent administration1



Use with caution and reduce iloperidone dosage by 50% during concurrent administration; resume previous iloperidone dosage upon discontinuance of paroxetine1


Reduce iloperidone dosage by about 50% if given concurrently with both paroxetine (a CYP2D6 inhibitor) and a CYP3A4 inhibitor1



Pentamidine



Increased risk of QT-interval prolongation1



Avoid concomitant use1



Smoking



Pharmacokinetic interaction unlikely1



Tetrabenazine



Increased risk of QT-interval prolongation1 83



Avoid concomitant use1 83


Iloperidonesee Pharmacokinetics


Absorption


Bioavailability


Well absorbed following oral administration; peak plasma concentrations achieved within 2–4 hours.1 10 12 15 Steady-state concentrations of iloperidone and its 2 main metabolites, P88 and P95, attained within 3–4 days.1 10


Food


Standard high-fat meal did not substantially affect peak plasma concentrations or AUCs of iloperidone, P88, or P95; however, time to reach peak plasma concentrations was delayed by 1, 2, and 6 hours, respectively.1 7 9 10 15


Special Populations


In patients with mild or moderate hepatic impairment, the pharmacokinetic profiles of iloperidone and P88 were not substantially altered in a single-dose study; however, exposure to P88 was substantially increased compared with healthy individuals.13 15


Renal impairment (Clcr <30 mL/minute) minimally affected peak plasma concentrations of iloperidone, P88, and P95 in a single-dose study.1 AUCs increased by 24% for iloperidone, decreased by 6% for P88, and increased by 52% for P95.1


Poor metabolizers of CYP2D6 have higher exposure to iloperidone compared with extensive metabolizers.1 10


Distribution


Extent


Iloperidone distributes into milk in rats; not known whether iloperidone and its metabolites distribute into human milk.1


Plasma Protein Binding


Iloperidone and its metabolites: Approximately 93–95%.1 8 12 13


Elimination


Metabolism


Metabolized mainly by carbonyl reduction, hydroxylation (mediated by CYP2D6), and O-demethylation (mediated by CYP3A4) to 2 main metabolites, P95 and P88; these metabolites undergo further oxidation and/or conjugation with glucuronic acid.1 8 9 10 (See Actions.)


Elimination Route


Radiolabeled drug is mostly eliminated in urine (about 58 and 45% in extensive and poor metabolizers of CYP2D6, respectively),1 with feces accounting for about 20% (extensive metabolizers) to 22% (poor metabolizers).1


Half-life


Mean elimination half-lives for iloperidone, P88, and P95 are 18, 26, and 23 hours, respectively, in extensive metabolizers of CYP2D6 and 33, 37, and 31 hours, respectively, in poor metabolizers.1 10 15


Stability


Storage


Oral


Tablets

25°C (may be exposed to 15–30°C); protect from light and moisture.1


ActionsActions



  • Exact mechanism of action of iloperidone and other antipsychotic agents in schizophrenia is unknown; efficacy may be mediated through a combination of antagonist activity at central dopamine type 2 (D2) and serotonin type 2 (5-hydroxytryptamine [5-HT2]) receptors.1 2 3 4 6 15




  • Exhibits high affinity for 5-HT2A and D2 and D3 receptors; moderate affinity for D4, 5-HT6 and 5-HT7, and α1-adrenergic receptors; and low affinity for 5-HT1A, D1, and histamine H1 receptors.1 2 3 4 6 7 8 10 11 12 13 14 15 Possesses no appreciable affinity for muscarinic cholinergic receptors.1 7 11 15




  • Functions as an antagonist at D2 and D3, 5-HT1A, and α1- and α2C-adrenergic receptors.1




  • Iloperidone has 2 main metabolites, P88 and P95; the affinity of P88 is generally equal to or less than that of iloperidone while P95 only demonstrates affinity for 5-HT2A and α1A-, α1B-, α1D-, and α2C-adrenergic receptors.1 8 10 13 15



Advice to Patients



  • Importance of advising patients and caregivers that geriatric patients with dementia-related psychosis treated with antipsychotic agents are at an increased risk of death.1 22 23 Importance of informing patients and caregivers that iloperidone is not approved for treating geriatric patients with dementia-related psychosis.1




  • Importance of patients immediately informing their clinician if they feel faint, lose consciousness, or have heart palpitations.1 Importance of counseling patients not to take iloperidone with other drugs that prolong the QT interval.1 Importance of instructing patients to inform clinicians that they are taking iloperidone before they take any new drug.1




  • Importance of informing patients and caregivers about the risk of NMS, which can cause high fever, stiff muscles, sweating, fast or irregular heart beat, change in BP, and confusion.1




  • Risk of orthostatic hypotension, especially when initiating or reinitiating treatment or increasing the dosage.1




  • Importance of informing patients in whom chronic iloperidone use is contemplated about the risk of tardive dyskinesia.1 Importance of informing patients to report any muscle movements that cannot be stopped to a healthcare professional.1




  • Risk of somnolence (i.e., sleepiness, drowsiness) and impaired judgment, thinking, or motor skills; importance of advising patients to exercise caution when performing activities requiring mental alertness (e.g., driving, operating hazardous machinery) until they gain experience with the drug’s effects.1




  • Importance of avoiding alcohol during iloperidone therapy.1




  • Importance of avoiding overheating or dehydration.1




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, dietary supplements, and/or herbal products, as well as any concomitant illnesses (e.g., cardiovascular disease, diabetes mellitus, seizures).1




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 90 Importance of clinicians informing patients about the benefits and risks of taking antipsychotics during pregnancy (see Pregnancy under Cautions).1 90 Importance of advising patients not to stop taking iloperidone if they become pregnant without consulting their clinician; abruptly stopping antipsychotic agents may cause complications.90 Importance of advising patients not to breast-feed during iloperidone therapy.1




  • Importance of informing patients of other important precautionary information.1 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
















































Iloperidone

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets



1 mg



Fanapt



Novartis



2 mg



Fanapt



Novartis



4 mg



Fanapt



Novartis



6 mg



Fanapt



Novartis



8 mg



Fanapt



Novartis



10 mg



Fanapt



Novartis



12 mg



Fanapt



Novartis



Titration Pack



2 Tablets, Iloperidone 1 mg (Fanapt)


2 Tablets, Iloperidone 2 mg (Fanapt)


2 Tablets, Iloperidone 4 mg (Fanapt)


2 Tablets, Iloperidone 6 mg (Fanapt)



Fanapt Titration Pack



Novartis



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions

Tuesday, 24 April 2012

Nitrofurantoin Suspension



Pronunciation: NYE-troe-fure-AN-toin
Generic Name: Nitrofurantoin
Brand Name: Furadantin


Nitrofurantoin Suspension is used for:

Treating and preventing urinary tract infections caused by certain bacteria.


Nitrofurantoin Suspension is an antibiotic for specific use in the urinary tract. It works by killing sensitive bacteria.


Do NOT use Nitrofurantoin Suspension if:


  • you are allergic to any ingredient in Nitrofurantoin Suspension

  • you are pregnant and at term (38 to 42 weeks pregnant), you are about to go into labor, or you are in labor

  • if you have decreased kidney function or decreased urination, or if you are unable to urinate

  • you have a history of liver problems or yellowing of the skin or eyes after taking any form of Nitrofurantoin Suspension

  • the patient is younger than 1 month old

Contact your doctor or health care provider right away if any of these apply to you.



Before using Nitrofurantoin Suspension:


Some medical conditions may interact with Nitrofurantoin Suspension. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have anemia, diabetes, blood electrolyte problems, glucose-6-phosphate dehydrogenase (G6PD) deficiency, kidney problems, liver problems, nerve problems (eg, peripheral neuropathy), porphyria (a certain blood problem), or low levels of vitamin B in your blood

  • if you have a history of lung problems (eg, diffuse interstitial pneumonitis, pulmonary fibrosis)

  • if you have very poor health

Some MEDICINES MAY INTERACT with Nitrofurantoin Suspension. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Probenecid or sulfinpyrazone because they may increase the risk of Nitrofurantoin Suspension's side effects or decrease Nitrofurantoin Suspension's effectiveness

This may not be a complete list of all interactions that may occur. Ask your health care provider if Nitrofurantoin Suspension may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Nitrofurantoin Suspension:


Use Nitrofurantoin Suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Nitrofurantoin Suspension by mouth with food.

  • Shake well before each use.

  • Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.

  • Drinking extra fluids while you are taking Nitrofurantoin Suspension is recommended. Check with your doctor for instructions.

  • Do not take an antacid that has magnesium trisilicate in it while you are taking Nitrofurantoin Suspension. Check with your pharmacist if you are unsure which antacids have magnesium trisilicate in them.

  • To clear up your infection completely, take Nitrofurantoin Suspension for the full course of treatment. Keep taking it even if you feel better in a few days.

  • If you miss a dose of Nitrofurantoin Suspension, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Nitrofurantoin Suspension.



Important safety information:


  • Nitrofurantoin Suspension may cause drowsiness or dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Nitrofurantoin Suspension with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Nitrofurantoin Suspension may rarely cause severe and sometimes fatal lung problems. If this occurs, it is usually in patients who take Nitrofurantoin Suspension for 6 months or longer. These problems may occur without warning signs. If you will be using Nitrofurantoin Suspension for a long period of time, your doctor may perform lung function tests to check for side effects. Tell your doctor right away if you develop fever, chills, chest pain, unusual cough, trouble breathing (especially while you are being active), other breathing problems, or persistent feeling of being unwell.

  • Nitrofurantoin Suspension may rarely cause severe and sometimes fatal liver problems. Tell your doctor right away if you develop yellowing of the skin or eyes; pale stools; or severe or persistent nausea, loss of appetite, or stomach pain.

  • Nitrofurantoin Suspension may rarely cause severe and sometimes fatal nerve problems. The risk may be greater in patients who have decreased kidney function, anemia, diabetes, electrolyte problems, or low blood vitamin B levels. Tell your doctor right away if you develop numbness, burning, or tingling in the hands or feet.

  • Mild diarrhea is common with antibiotic use. However, a more serious form of diarrhea (pseudomembranous colitis) may rarely occur. This may develop while you use the antibiotic or within several months after you stop using it. Contact your doctor right away if stomach pain or cramps, severe diarrhea, or bloody stools occur. Do not treat diarrhea without first checking with your doctor.

  • Long-term or repeated use of Nitrofurantoin Suspension may cause a second infection. Tell your doctor if signs of a second infection occur. Your medicine may need to be changed to treat this.

  • Nitrofurantoin Suspension only works against bacteria; it does not treat viral infections (eg, the common cold).

  • Be sure to use Nitrofurantoin Suspension for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The bacteria could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.

  • Nitrofurantoin Suspension may discolor the urine. This is normal and not a cause for concern.

  • Diabetes patients - Nitrofurantoin Suspension may cause the results of some tests for urine glucose to be wrong. Ask your doctor before you change your diet or the dose of your diabetes medicine.

  • Lab tests, including liver function, kidney function, and lung function, may be performed while you use Nitrofurantoin Suspension. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Nitrofurantoin Suspension with caution in the ELDERLY; they may be more sensitive to its effects, especially lung or liver problems.

  • Nitrofurantoin Suspension should not be used in CHILDREN younger than 1 month old; the risk of anemia may be greater in these children.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Nitrofurantoin Suspension while you are pregnant. Do NOT take Nitrofurantoin Suspension if you are at term (38 to 42 weeks pregnant), if you are about to go into labor, or if you are in labor. Nitrofurantoin Suspension is found in breast milk. Do not breast-feed infants younger than 1 month old while you are taking Nitrofurantoin Suspension. If your child is older than 1 month, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Nitrofurantoin Suspension:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Gas; headache; loss of appetite; mild diarrhea; nausea.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); bloody or watery stools; bluish skin or nails; blurred vision or other vision changes (eg, vision loss); butterfly-shaped rash on the nose and cheeks; confusion; eye pain; joint or muscle pain; mood or mental changes (eg, depression); persistent feeling of being unwell; red, swollen, blistered, or peeling skin; severe or persistent diarrhea; severe or persistent headache; severe stomach pain or cramps; symptoms of liver problems (eg, yellowing of the skin or eyes, dark urine, pale stools, severe or persistent nausea or loss of appetite, stomach pain); symptoms of lung problems (eg, fever, chills, chest pain, shortness of breath, unusual or persistent cough); tingling, numbness, or burning of the hands and feet; unusual bruising or bleeding; unusual tiredness or weakness.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Nitrofurantoin side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include vomiting.


Proper storage of Nitrofurantoin Suspension:

Store Nitrofurantoin Suspension in its original glass container at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Protect from freezing. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Nitrofurantoin Suspension out of the reach of children and away from pets.


General information:


  • If you have any questions about Nitrofurantoin Suspension, please talk with your doctor, pharmacist, or other health care provider.

  • Nitrofurantoin Suspension is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Nitrofurantoin Suspension. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Nitrofurantoin resources


  • Nitrofurantoin Side Effects (in more detail)
  • Nitrofurantoin Use in Pregnancy & Breastfeeding
  • Drug Images
  • Nitrofurantoin Drug Interactions
  • Nitrofurantoin Support Group
  • 78 Reviews for Nitrofurantoin - Add your own review/rating


Compare Nitrofurantoin with other medications


  • Bladder Infection
  • Prevention of Bladder infection
  • Urinary Tract Infection

Pp-Cap


Generic Name: propoxyphene (Oral route)

proe-POX-i-feen

Oral route(Capsule)

Do not prescribe propoxyphene for patients who are suicidal or addiction-prone. Prescribe propoxyphene with caution for patients taking tranquilizers or antidepressant drugs, and patients who use alcohol in excess. Patients should not exceed the recommended dose and alcohol intake should be limited. Propoxyphene products in excessive doses, either alone or in combination with other CNS depressants, including alcohol, are a major cause of drug-related deaths .


Oral route(Tablet)

Do not prescribe propoxyphene for patients who are suicidal or addiction-prone. Prescribe propoxyphene with caution for patients taking tranquilizers or antidepressant drugs, and patients who use alcohol in excess. Patients should not exceed the recommended dose and alcohol intake should be limited. Propoxyphene products in excessive doses, either alone or in combination with other CNS depressants, including alcohol, are a major cause of drug-related deaths .



Commonly used brand name(s)

In the U.S.


  • Darvon

  • Darvon-N

  • Pp-Cap

Available Dosage Forms:


  • Capsule

  • Tablet

  • Suspension

Therapeutic Class: Analgesic


Chemical Class: Opioid


Uses For Pp-Cap


Propoxyphene is used to relieve mild to moderate pain. It belongs to the group of medicines called narcotic analgesics (pain medicines). It acts on the central nervous system (CNS) to relieve pain.


When propoxyphene is used for a long time, it may become habit-forming, causing mental or physical dependence. However, people who have continuing pain should not let the fear of dependence keep them from using narcotics to relieve their pain. Mental dependence (addiction) is not likely to occur when narcotics are used for this purpose. Physical dependence may lead to withdrawal side effects if treatment is stopped suddenly. However, severe withdrawal side effects can usually be prevented by gradually reducing the dose over a period of time before treatment is stopped completely.


Products containing propoxyphene were withdrawn from the U.S. market starting November 19, 2010.


This medicine was available only with your doctor's prescription.


Before Using Pp-Cap


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of propoxyphene in the pediatric population. Safety and efficacy have not been established.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of propoxyphene in the elderly. However, elderly patients are more likely to have age-related liver, kidney, or heart problems which may require caution and an adjustment in the dose for patients receiving propoxyphene.


Breast Feeding


Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Naltrexone

  • Rasagiline

  • Selegiline

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Adinazolam

  • Alfentanil

  • Alprazolam

  • Amobarbital

  • Anileridine

  • Aprobarbital

  • Bromazepam

  • Brotizolam

  • Buprenorphine

  • Butabarbital

  • Butalbital

  • Butorphanol

  • Carbamazepine

  • Carisoprodol

  • Chloral Hydrate

  • Chlordiazepoxide

  • Chlorzoxazone

  • Clobazam

  • Clonazepam

  • Clorazepate

  • Codeine

  • Dantrolene

  • Dezocine

  • Diazepam

  • Estazolam

  • Ethchlorvynol

  • Fentanyl

  • Flunitrazepam

  • Flurazepam

  • Fospropofol

  • Halazepam

  • Hydrocodone

  • Hydromorphone

  • Ketazolam

  • Levorphanol

  • Lorazepam

  • Lormetazepam

  • Medazepam

  • Meperidine

  • Mephenesin

  • Mephobarbital

  • Meprobamate

  • Metaxalone

  • Methocarbamol

  • Methohexital

  • Midazolam

  • Morphine

  • Morphine Sulfate Liposome

  • Nalbuphine

  • Nitrazepam

  • Nordazepam

  • Opium

  • Oxazepam

  • Oxycodone

  • Oxymorphone

  • Pentazocine

  • Pentobarbital

  • Phenobarbital

  • Prazepam

  • Propoxyphene

  • Quazepam

  • Remifentanil

  • Secobarbital

  • Sodium Oxybate

  • Sufentanil

  • Tapentadol

  • Temazepam

  • Thiopental

  • Triazolam

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Doxepin

  • Metoprolol

  • Propranolol

  • Warfarin

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Alcohol abuse, history of or

  • Breathing problems (e.g., chronic obstructive pulmonary disease [COPD], cor pulmonale, hypoxia) or

  • Drug dependence, especially narcotic abuse or dependence, or history of—Use with caution. May increase risk for more serious side effects.

  • Brain tumor or

  • Head injuries or

  • Increased pressure in the head—Some of the side effects of propoxyphene can cause serious problems in people who have these medical problems.

  • Breathing problems (e.g., asthma, hypercapnia), severe or

  • Emotional problems or

  • Paralytic ileus (intestinal blockage) or

  • Respiratory depression (hypoventilation or slow breathing) or

  • Suicidal ideation (thoughts of hurting or killing oneself), or history of—Should not be used in patients with these conditions.

  • Hypotension (low blood pressure) or

  • Pancreatitis (inflammation of the pancreas)—Use with caution. May make these conditions worse.

  • Kidney disease or

  • Liver disease—Use with caution. The effects may be increased because of slower removal of the medicine from the body.

Proper Use of propoxyphene

This section provides information on the proper use of a number of products that contain propoxyphene. It may not be specific to Pp-Cap. Please read with care.


Take this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. This is especially important for elderly patients, who may be more sensitive to the effects of pain medicines. If too much of this medicine is taken for a long time, it may become habit-forming (causing mental or physical dependence).


This medicine should come with a Medication Guide. Read and follow these instructions carefully. Ask your doctor if you have any questions.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For oral dosage forms (capsules or tablets):
    • For mild to moderate pain:
      • Adults—One capsule or tablet every 4 hours as needed. However, the dose is usually not more than 6 capsules or tablets per day.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Throw any unused medicine by mixing it with used coffee grounds or kitty litter and place it in a sealable bag, empty can, or container.


Precautions While Using Pp-Cap


It is very important that your doctor check your progress while you are taking this medicine. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it.


Talk to your doctor first before you stop taking this medicine and changing to another pain medicine.


This medicine can cause changes in heart rhythms, such as conditions called PR, QRS, and QT prolongation. It may change the way your heart beats and cause fainting, dizziness, lightheadedness, or serious side effects in some patients. Contact your doctor right away if you have any symptoms of heart rhythm problems, such as fast, pounding, or irregular heartbeats.


This medicine will add to the effects of alcohol and other CNS depressants (medicines that can make you drowsy or less alert). Some examples of CNS depressants are antihistamines or medicine for allergies or colds; sedatives, tranquilizers, or sleeping medicine; other prescription pain medicine or narcotics; medicine for seizures or barbiturates; muscle relaxants; or anesthetics, including some dental anesthetics. Check with your doctor before taking any of the other medicines listed above while you are using this medicine.


This medicine may be habit-forming. If you feel that the medicine is not working as well, do not use more than your prescribed dose.


Dizziness, lightheadedness, or fainting may occur when you get up suddenly from a lying or sitting position. Getting up slowly may help lessen this problem. Also, lying down for a while may relieve dizziness or lightheadedness.


This medicine may make you dizzy, drowsy, or lightheaded. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or not alert.


Using narcotics for a long time can cause severe constipation. To prevent this, your doctor may direct you to take laxatives, drink a lot of fluids, or increase the amount of fiber in your diet. Be sure to follow the directions carefully, because continuing constipation can lead to more serious problems.


Do not change your dose or suddenly stop using this medicine without first checking with your doctor. Your doctor may want you to gradually reduce the amount you are using before stopping it completely. This may help prevent worsening of your condition and reduce the possibility of withdrawal symptoms, such as abdominal or stomach cramps, anxiety, fever, nausea, runny nose, sweating, tremors, or trouble with sleeping.


Using this medicine while you are pregnant may cause neonatal withdrawal syndrome in your newborn babies. Tell your doctor right away if your child has the following symptoms: abnormal sleep pattern, diarrhea, high-pitched cry, irritability, shakiness or tremor, weight loss, vomiting, or failure to gain weight.


Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.


Pp-Cap Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Rare
  • Abdominal or stomach pain

  • chills

  • clay-colored stools

  • dark urine

  • dizziness

  • fever

  • headache

  • itching

  • loss of appetite

  • nausea

  • rash

  • unpleasant breath odor

  • unusual tiredness or weakness

  • vomiting of blood

  • yellow eyes or skin

Incidence not known
  • Bloating

  • bloody or black, tarry stools

  • bloody or cloudy urine

  • change in consciousness

  • chest pain or discomfort

  • confusion

  • constipation

  • darkened urine

  • decreased urine output

  • difficult or troubled breathing

  • dilated neck veins

  • drowsiness

  • extreme fatigue

  • fainting

  • fast, slow, pounding, or irregular heartbeat or pulse

  • fever with or without chills

  • hives

  • hoarseness

  • indigestion

  • irregular, fast or slow, or shallow breathing

  • irritation

  • itching

  • joint pain, stiffness, or swelling

  • light-colored stools

  • loss of consciousness

  • muscle tremors

  • no blood pressure or pulse

  • no breathing

  • pain or discomfort in the arms, jaw, back, or neck

  • pains in the stomach, side, or abdomen, possibly radiating to the back

  • pale or blue lips, fingernails, or skin

  • rapid, deep breathing

  • redness of the skin

  • restlessness

  • right upper abdominal or stomach pain and fullness

  • severe stomach pain

  • shakiness and unsteady walk

  • shortness of breath

  • stomach cramps

  • stopping of the heart

  • sudden decrease in the amount of urine

  • swelling of the eyelids, face, fingers, lips, hands, lower legs, or feet

  • thoughts of suicide

  • tightness in the chest

  • troubled breathing or swallowing

  • unconsciousness

  • unsteadiness, trembling, or other problems with muscle control or coordination

  • vomiting of blood or material that looks like coffee grounds

  • weight gain

  • wheezing

Get emergency help immediately if any of the following symptoms of overdose occur:


Symptoms of overdose
  • Bluish color of the fingernails, lips, skin, palms, or nail beds

  • convulsion

  • coughing that sometimes produces a pink frothy sputum

  • decreased awareness or responsiveness

  • difficult, fast, or noisy breathing, sometimes with wheezing

  • dilated pupils

  • muscle tremors

  • pale skin

  • pounding or rapid pulse

  • rapid, deep breathing

  • severe sleepiness

  • sleepiness or unusual drowsiness

  • slow to respond

  • slurred speech

  • weight loss

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Relaxed and calm

Incidence not known
  • Abnormal behavior

  • blurred or loss of vision

  • diarrhea

  • disturbed color perception

  • double vision

  • false or unusual sense of well-being

  • halos around lights

  • mental depression or anxiety

  • muscular pain, tenderness, wasting, or weakness

  • night blindness

  • nightmares or unusually vivid dreams

  • overbright appearance of lights

  • seeing, hearing, or feeling things that are not there

  • swelling of the eye

  • tunnel vision

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Pp-Cap side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Pp-Cap resources


  • Pp-Cap Side Effects (in more detail)
  • Pp-Cap Use in Pregnancy & Breastfeeding
  • Pp-Cap Drug Interactions
  • Pp-Cap Support Group
  • 0 Reviews for Pp-Cap - Add your own review/rating


  • Propoxyphene Professional Patient Advice (Wolters Kluwer)

  • Darvon Prescribing Information (FDA)

  • Darvon Concise Consumer Information (Cerner Multum)

  • Darvon MedFacts Consumer Leaflet (Wolters Kluwer)

  • Darvon-N Prescribing Information (FDA)

  • Propoxyphene Hydrochloride Monograph (AHFS DI)



Compare Pp-Cap with other medications


  • Pain

Saturday, 21 April 2012

Arsenic Poisoning, Mild Medications


There are currently no drugs listed for "Arsenic Poisoning, Mild". See Arsenic Poisoning.





Drug List:

Timolide


Generic Name: Hydrochlorothiazide/Timolol (hye-droe-klor-oh-THYE-a-zide/TIM-oh-lole)
Brand Name: Timolide

Do not suddenly stop taking Timolide. Sharp chest pain, irregular heartbeat, and sometimes heart attack may occur if you suddenly stop Timolide. The risk may be greater if you have certain types of heart disease. Your doctor should slowly lower your dose over several weeks if you need to stop taking it. This should be done even if you only take Timolide for high blood pressure. Heart disease is common and you may not know you have it. Limit physical activity while you are lowering your dose. If new or worsened chest pain or other heart problems occur, contact your doctor right away. You may need to start taking Timolide again.





Timolide is used for:

Treating high blood pressure.


Timolide is a beta-blocker and diuretic combination. It works by decreasing the force and slowing down the heartbeat, helping the heart beat more regularly and reducing the amount of work the heart has to do. It also increases the elimination of excessive fluid, which helps to decrease blood pressure.


Do NOT use Timolide if:


  • you are allergic to any ingredient in Timolide or to sulfonamide medicines (eg, sulfamethoxazole, probenecid, glyburide)

  • you have uncontrolled heart failure, heart block, heart shock, a very slow heart rate, or low blood pressure

  • you are unable to urinate or have a history of asthma or severe chronic obstructive pulmonary disease (COPD)

  • you are taking other beta-blockers (eg, propranolol), dofetilide, or mibefradil

Contact your doctor or health care provider right away if any of these apply to you.



Before using Timolide:


Some medical conditions may interact with Timolide. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of bronchitis, lung disease (eg, COPD), diabetes, gout, an overactive thyroid, heart problems (eg, congestive heart failure), blood vessel problems, pheochromocytoma, lupus, liver disease, kidney problems, or abnormal blood electrolyte (eg, potassium sodium) levels

  • if you are having surgery, receiving anesthesia, or you are dehydrated

Some MEDICINES MAY INTERACT with Timolide. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Barbiturates (eg, phenobarbital), cimetidine, clonidine, corticosteroids (eg, prednisone), guanethidine, other beta-blockers (eg, propranolol), or reserpine because they may increase the risk of Timolide's side effects

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen), phenytoin, or rifampin because they may decrease Timolide's effectiveness

  • Antiarrhythmics (eg, disopyramide), calcium channel blockers (eg, verapamil, diltiazem), or cimetidine because side effects, such as slow or irregular heart beat or low blood pressure, may occur

  • Angiotensin-converting enzyme (ACE) inhibitors (eg, enalapril), barbiturates (eg, phenobarbital), chlorpromazine, clonidine, diazoxide, flecainide, mefloquine, mibefradil, narcotics (eg, codeine), or nifedipine because the risk of side effects of both medicines may be increased

  • Allopurinol, amantadine, digitalis (eg, digoxin), dofetilide, insulin or other medicines for diabetes (eg, glyburide), ketanserin, lithium, theophylline, or thyroxine because the risk of their side effects may be increased by Timolide

This may not be a complete list of all interactions that may occur. Ask your health care provider if Timolide may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Timolide:


Use Timolide as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Timolide by mouth with or without food.

  • If you also take cholestyramine or colestipol, do not take them within 1 before or 2 hours after taking Timolide. Check with your doctor if you have questions.

  • Timolide may increase the amount of urine or cause you to urinate more often when you first start taking it. To keep this from disturbing your sleep, try to take your dose before 6 pm.

  • If you miss a dose of Timolide, take the missed dose if you remember the same day. Skip the missed dose if you do not remember the same day. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Timolide.



Important safety information:


  • Timolide may cause drowsiness, dizziness, or lightheadedness. These effects may be worse if you take it with alcohol or certain medicines. Use Timolide with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Timolide may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.

  • Patients who take medicine for high blood pressure often feel tired or run down for a few weeks after starting treatment. Be sure to take your medicine even if you may not feel "normal." Tell your doctor if you develop any new symptoms.

  • Timolide may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Timolide. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.

  • Tell your doctor or dentist that you take Timolide before you receive any medical or dental care, emergency care, or surgery.

  • If you have high blood pressure, do not use nonprescription products that contain stimulants. These products may include diet pills or cold medicines. Contact your doctor if you have any questions or concerns.

  • Diabetes patients - Timolide may hide signs of low blood sugar, such as a rapid heartbeat. Be sure to watch for other signs of low blood sugar. Low blood sugar may make you anxious, sweaty, weak, dizzy, drowsy, or faint. It may also make your vision change; give you a headache, chills, or tremors; or make you more hungry. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.

  • Timolide may interfere with certain lab tests, including parathyroid function tests. Be sure your doctor and lab personnel know you are taking Timolide.

  • Lab tests, including blood pressure, blood electrolyte levels, and heart rate, may be performed while you use Timolide. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Timolide with caution in the ELDERLY; they may be more sensitive to its effects.

  • Timolide should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Timolide while you are pregnant. Timolide is found in breast milk. Do not breast-feed while taking Timolide.


Possible side effects of Timolide:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Cough; dizziness; drowsiness; lightheadedness; tiredness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; confusion; decreased urination; dry mouth; loss of consciousness; muscle pain or weakness; nausea; slow or irregular heartbeat; swelling of ankles or feet; tremors; unusual thirst or fatigue; vomiting.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Timolide side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include coughing; dizziness; drowsiness; fainting; loss of consciousness; muscular weakness; nausea; seizures; slow heartbeat; trouble breathing; upset stomach; vomiting; weakness.


Proper storage of Timolide:

Store Timolide at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Timolide out of the reach of children and away from pets.


General information:


  • If you have any questions about Timolide, please talk with your doctor, pharmacist, or other health care provider.

  • Timolide is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

This information is a summary only. It does not contain all information about Timolide. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Timolide resources


  • Timolide Side Effects (in more detail)
  • Timolide Use in Pregnancy & Breastfeeding
  • Timolide Drug Interactions
  • Timolide Support Group
  • 0 Reviews for Timolide - Add your own review/rating


Compare Timolide with other medications


  • High Blood Pressure